 Jeffrey Schowinsky
Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 8 | 2024 | 688 | 0.800 |
Why?
| | Mycosis Fungoides | 2 | 2018 | 63 | 0.590 |
Why?
| | Azacitidine | 4 | 2023 | 157 | 0.530 |
Why?
| | Brain Neoplasms | 3 | 2018 | 1331 | 0.520 |
Why?
| | Lipomatosis | 1 | 2015 | 4 | 0.450 |
Why?
| | HMGA2 Protein | 1 | 2015 | 10 | 0.440 |
Why?
| | Adamantinoma | 1 | 2015 | 4 | 0.440 |
Why?
| | Synovial Membrane | 1 | 2015 | 123 | 0.400 |
Why?
| | Tibia | 1 | 2015 | 176 | 0.390 |
Why?
| | Eosinophilia | 1 | 2015 | 224 | 0.380 |
Why?
| | Keratins | 3 | 2026 | 171 | 0.380 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2017 | 992 | 0.370 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2012 | 20 | 0.350 |
Why?
| | Skin Neoplasms | 2 | 2018 | 852 | 0.350 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2012 | 83 | 0.330 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 6 | 2023 | 280 | 0.320 |
Why?
| | Sulfonamides | 6 | 2023 | 583 | 0.280 |
Why?
| | Soft Tissue Neoplasms | 2 | 2023 | 131 | 0.270 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1969 | 0.260 |
Why?
| | Dendritic Cell Sarcoma, Follicular | 1 | 2026 | 4 | 0.240 |
Why?
| | Epithelioid Cells | 1 | 2026 | 9 | 0.230 |
Why?
| | Clonal Evolution | 2 | 2017 | 47 | 0.230 |
Why?
| | Biopsy, Needle | 1 | 2006 | 185 | 0.230 |
Why?
| | Pleural Neoplasms | 1 | 2026 | 31 | 0.230 |
Why?
| | Diagnostic Errors | 1 | 2006 | 178 | 0.220 |
Why?
| | Rectum | 1 | 2006 | 182 | 0.220 |
Why?
| | Tissue Scaffolds | 1 | 2024 | 221 | 0.180 |
Why?
| | Carrier Proteins | 2 | 2017 | 729 | 0.180 |
Why?
| | Surgical Wound Infection | 1 | 2024 | 329 | 0.170 |
Why?
| | Nuclear Proteins | 2 | 2017 | 740 | 0.170 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.170 |
Why?
| | Mastocytosis | 1 | 2021 | 14 | 0.160 |
Why?
| | Extracellular Matrix | 1 | 2024 | 562 | 0.160 |
Why?
| | Biomarkers, Tumor | 3 | 2026 | 1329 | 0.160 |
Why?
| | Adenocarcinoma | 1 | 2006 | 926 | 0.140 |
Why?
| | Prostatic Neoplasms | 1 | 2006 | 981 | 0.140 |
Why?
| | Fatal Outcome | 2 | 2018 | 305 | 0.140 |
Why?
| | Humans | 28 | 2026 | 145750 | 0.130 |
Why?
| | Tetrahydronaphthalenes | 1 | 2017 | 34 | 0.130 |
Why?
| | Leukemia, Neutrophilic, Chronic | 1 | 2017 | 5 | 0.130 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2017 | 7 | 0.130 |
Why?
| | Valine | 1 | 2017 | 83 | 0.130 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2017 | 78 | 0.130 |
Why?
| | Immunohistochemistry | 2 | 2026 | 1723 | 0.120 |
Why?
| | Pyrazoles | 2 | 2021 | 517 | 0.120 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 53 | 0.120 |
Why?
| | Genetic Association Studies | 1 | 2018 | 371 | 0.120 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2016 | 8 | 0.120 |
Why?
| | Skull Base Neoplasms | 1 | 2016 | 30 | 0.120 |
Why?
| | Mutation | 3 | 2017 | 4090 | 0.120 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 5 | 0.120 |
Why?
| | Leukocytosis | 1 | 2015 | 32 | 0.120 |
Why?
| | Gene Frequency | 1 | 2017 | 489 | 0.110 |
Why?
| | Lymphoma | 1 | 2017 | 241 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 4 | 2016 | 3915 | 0.110 |
Why?
| | Neoplasm, Residual | 3 | 2023 | 143 | 0.110 |
Why?
| | Tenosynovitis | 1 | 2015 | 11 | 0.110 |
Why?
| | Lipoma | 1 | 2015 | 17 | 0.110 |
Why?
| | Natalizumab | 2 | 2012 | 41 | 0.110 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 266 | 0.110 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 297 | 0.110 |
Why?
| | Middle Aged | 9 | 2026 | 36297 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 883 | 0.100 |
Why?
| | Diagnosis, Differential | 3 | 2026 | 1512 | 0.100 |
Why?
| | Tissue Culture Techniques | 1 | 2013 | 82 | 0.100 |
Why?
| | Male | 14 | 2026 | 72992 | 0.100 |
Why?
| | Genomic Instability | 1 | 2013 | 68 | 0.090 |
Why?
| | Induction Chemotherapy | 2 | 2024 | 88 | 0.090 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2012 | 20 | 0.090 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2012 | 38 | 0.090 |
Why?
| | Membrane Glycoproteins | 1 | 2015 | 499 | 0.090 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2018 | 337 | 0.090 |
Why?
| | Ki-67 Antigen | 1 | 2012 | 118 | 0.090 |
Why?
| | CD3 Complex | 1 | 2012 | 112 | 0.090 |
Why?
| | Female | 14 | 2026 | 79025 | 0.090 |
Why?
| | Prognosis | 4 | 2024 | 4329 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2015 | 339 | 0.080 |
Why?
| | Leukocyte Count | 2 | 2024 | 318 | 0.080 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1505 | 0.080 |
Why?
| | Immunologic Factors | 1 | 2012 | 260 | 0.080 |
Why?
| | Neutrophils | 1 | 2015 | 1125 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2399 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 1150 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2017 | 2219 | 0.070 |
Why?
| | Lymphatic Diseases | 1 | 2008 | 21 | 0.070 |
Why?
| | Bone Marrow | 3 | 2017 | 307 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2015 | 1166 | 0.070 |
Why?
| | Neutropenia | 1 | 2008 | 154 | 0.060 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2007 | 58 | 0.060 |
Why?
| | Adult | 8 | 2024 | 40867 | 0.060 |
Why?
| | Racemases and Epimerases | 1 | 2006 | 11 | 0.060 |
Why?
| | Chromosome Aberrations | 2 | 2018 | 166 | 0.060 |
Why?
| | Pleura | 1 | 2026 | 28 | 0.060 |
Why?
| | Mucins | 1 | 2006 | 75 | 0.060 |
Why?
| | Retrospective Studies | 5 | 2024 | 17322 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2016 | 2770 | 0.060 |
Why?
| | Prostate-Specific Antigen | 1 | 2006 | 161 | 0.060 |
Why?
| | Aged | 6 | 2024 | 26212 | 0.060 |
Why?
| | Carcinoma, Renal Cell | 1 | 2007 | 230 | 0.050 |
Why?
| | Hyphae | 1 | 2024 | 11 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2024 | 11793 | 0.050 |
Why?
| | Fungi | 1 | 2024 | 121 | 0.050 |
Why?
| | Biopsy | 2 | 2018 | 1082 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 90 | 0.050 |
Why?
| | Cytodiagnosis | 1 | 2023 | 31 | 0.050 |
Why?
| | Biopsy, Fine-Needle | 1 | 2023 | 74 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 414 | 0.050 |
Why?
| | World Health Organization | 1 | 2023 | 104 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2021 | 8346 | 0.050 |
Why?
| | Disease Progression | 2 | 2023 | 2865 | 0.050 |
Why?
| | Wound Healing | 1 | 2024 | 355 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2007 | 777 | 0.040 |
Why?
| | Triazines | 1 | 2021 | 49 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2006 | 675 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2018 | 1165 | 0.040 |
Why?
| | Pyrroles | 1 | 2021 | 220 | 0.040 |
Why?
| | Neoplastic Stem Cells | 1 | 2023 | 409 | 0.040 |
Why?
| | Young Adult | 3 | 2024 | 14250 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5428 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 307 | 0.040 |
Why?
| | Karyotyping | 1 | 2018 | 106 | 0.040 |
Why?
| | Histocytochemistry | 1 | 2018 | 78 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 699 | 0.030 |
Why?
| | Temporomandibular Joint | 1 | 2016 | 8 | 0.030 |
Why?
| | Genetic Testing | 1 | 2019 | 483 | 0.030 |
Why?
| | Occipital Bone | 1 | 2016 | 18 | 0.030 |
Why?
| | Sphenoid Bone | 1 | 2016 | 15 | 0.030 |
Why?
| | Frontal Bone | 1 | 2016 | 19 | 0.030 |
Why?
| | Cranial Fossa, Middle | 1 | 2016 | 19 | 0.030 |
Why?
| | Temporal Bone | 1 | 2016 | 48 | 0.030 |
Why?
| | Nitriles | 1 | 2017 | 211 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 222 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 343 | 0.030 |
Why?
| | Administration, Oral | 1 | 2017 | 867 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 410 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 328 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1139 | 0.030 |
Why?
| | Karyotype | 1 | 2013 | 19 | 0.020 |
Why?
| | Odds Ratio | 1 | 2016 | 1083 | 0.020 |
Why?
| | Pyrimidines | 1 | 2017 | 530 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 246 | 0.020 |
Why?
| | Heterografts | 1 | 2013 | 143 | 0.020 |
Why?
| | Chondrogenesis | 1 | 2013 | 88 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2013 | 322 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 680 | 0.020 |
Why?
| | Carcinogenesis | 1 | 2013 | 228 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2017 | 981 | 0.020 |
Why?
| | Infant | 2 | 2018 | 10089 | 0.020 |
Why?
| | Genetic Variation | 1 | 2013 | 976 | 0.020 |
Why?
| | Leukocyte Elastase | 1 | 2008 | 75 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2069 | 0.020 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 489 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7133 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 923 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2013 | 2514 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2013 | 2051 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3551 | 0.010 |
Why?
| | Brain | 1 | 2012 | 2969 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 22569 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2008 | 6464 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18357 | 0.010 |
Why?
| | Animals | 1 | 2013 | 38100 | 0.010 |
Why?
| | Child | 1 | 2008 | 22738 | 0.000 |
Why?
|
|
Schowinsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|